Now, Tedder and colleagues help to resolve this issue by showing that B-cell depletion with a CD20-specific antibody has opposing effects on the severity of EAE depending on whether treatment is ...

Clinical studies with rituximab, a regulatory approved CD20-specific monoclonal antibody, have shown that B-cell depletion is efficacious in autoimmune diseases such as rheumatoid arthritis.

The potentially first-in-class drug, which targets CD20, is able to achieve "deep B-cell depletion" by stimulating cells of the immune system to engulf and destroy B-cells in the presence of a ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...